Enteris expands manufacturing, launches CDMO business unit

By The Science Advisory Board staff writers

May 3, 2021 -- Enteris BioPharma has expanded its Boonton, NJ, manufacturing facility and launched a contract development and manufacturing organization (CDMO) business unit.

The two actions will help the firm further develop and manufacture solid oral doses for biopharmaceutics classification system (BCS) III and IV compounds, it said.

The expanded facility is 32,000 sq ft, of which 6,000 sq ft is cleanroom space and 2,500 is for containment and processing of high-potency active pharmaceutical ingredients (APIs).

Porton Biologics establishes CGT CDMO services with $61.4M in financing
Porton Biologics, a subsidiary of cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) Porton Pharma Solutions, has...
Quotient Sciences acquires CDMO Arcinova
Quotient Sciences has purchased U.K. multiservice contract development and manufacturing organization (CDMO) Arcinova.
Eurofins CDMO expands drug product operations in Canada
Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing...
Agilent unveils new handheld raw material ID system
Agilent Technologies has launched Vaya Raman, a handheld raw material identity verification system for pharmaceutical manufacturers.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter